Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Auson Pharmaceuticals Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners and are distributed across the distinct art units.
The busiest examiner for the company is ROBINSON, MIKHAIL O'DONNEL, who is responsible for 1 pending office action. This examiner handles 1 of the pending office actions currently facing the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, MIKHAIL O'DONNEL | 1 | 58.3% | +43.1% |
| ARCORIA, PAUL JOSEPH | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18901715 | PHARMACEUTICAL COMPOSITION OF DILTIAZEM HYDROCHLORIDE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ARCORIA, PAUL JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19029021 | TIMOLOL MALEATE GEL FOR TOPICAL ADMINISTRATION | ROBINSON, MIKHAIL O'DONNEL | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19029021 | TIMOLOL MALEATE GEL FOR TOPICAL ADMINISTRATION | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103§112DP | Non-Final OA | — | Pending | Jan 17, 2025 |
| 18901715 | PHARMACEUTICAL COMPOSITION OF DILTIAZEM HYDROCHLORIDE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ARCORIA, PAUL JOSEPH | 1621 | §103§112 | Non-Final OA | — | Pending | Sep 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAuson Pharmaceuticals Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Mikhail O'Donnel Robinson has the most, with 1 of Auson Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
